Palatin Technologies, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

x No fee required.

1) Title of each class of securities to which transaction applies:

2) Aggregate number of securities to which transaction applies:

3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

4) Proposed maximum aggregate value of transaction:
5) Total fee paid:

- Fee paid previously with preliminary materials.

- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

  1) Amount Previously Paid:

  2) Form, Schedule or Registration Statement No.:

  3) Filing Party:

  4) Date Filed:

Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

PALATIN TECHNOLOGIES, INC.
4C Cedar Brook Drive
Cranbury, New Jersey 08512

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

DATE December 15, 2006

TIME 9:30 a.m., Eastern Time

PLACE Palatin's offices, 4C Cedar Brook Drive, Cranbury, New Jersey 08512

RECORD DATE October 19, 2006

ITEMS OF (1)election of directors;
BUSINESS

(2) ratification of appointment of our independent registered public accounting firm for the fiscal year ending June 30, 2007;
(3) other matters properly brought before the meeting.

STOCKHOLDER LIST

A list of all stockholders entitled to vote at the meeting will be available for examination by any stockholder, for any purpose germane to the meeting, during ordinary business hours for 10 days before the meeting, at our offices, Cedar Brook Corporate Center, 4C Cedar Brook Drive, Cranbury, New Jersey 08512.

By order of the board of directors,
STEPHEN T. WILLS, Secretary
November 8, 2006
YOUR VOTE IS IMPORTANT

Whether or not you plan to attend the meeting, please complete and return the enclosed proxy card. Your prompt voting may save us the expense of following up with a second mailing. We are sending these proxy materials to stockholders beginning on or about November 8, 2006.

METHODS OF VOTING

You may vote by signing and returning the enclosed proxy card or by voting in person at the meeting. If you send in a proxy card, and also attend the meeting in person, the proxy holders will vote your shares as you instructed on your proxy card, unless you inform the Secretary at the meeting that you wish to vote in person.

REVOKING A PROXY

You may revoke your proxy by:

- signing and returning another proxy card at a later date;
- sending written notice of revocation to the Secretary at our offices, 4C Cedar Brook Drive, Cranbury, New
To be effective, a later-dated proxy or written revocation must arrive at our corporate offices before the start of the meeting.

PROXY SOLICITATION

We are soliciting the enclosed proxy card on behalf of the board of directors, and we will pay all costs of preparing, assembling and mailing the proxy materials. In addition to mailing out proxy materials, our officers and employees may solicit proxies by telephone or fax, without receiving any additional compensation for their services. We have requested brokers, banks and other fiduciaries to forward proxy materials to the beneficial owners of our stock.

HOW PROXY CARDS ARE VOTED

The proxy holders named on the proxy card are Carl Spana, Ph.D., chief executive officer, president and a director, and Stephen T. Wills, chief financial officer, executive vice president, secretary and treasurer. The proxy holders will vote shares according to the stockholder's instructions on the proxy card. If a signed proxy card does not contain instructions, the proxy holders will vote the shares FOR the election of the director nominees listed on the card; FOR ratifying the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2007; and in their discretion on any other business which may properly come before the meeting.

QUORUM AND VOTES REQUIRED

A majority of the votes of outstanding shares of common stock and Series A preferred stock, represented at the meeting in person or by proxy, constitutes a quorum. Abstentions and broker non-votes will count towards the quorum. A broker non-vote occurs when a nominee holding shares for a beneficial owner does not vote on a particular proposal because the nominee does not have discretionary voting power for that particular item, and has not received instructions from the beneficial owner. Common stock and Series A preferred stock will vote together as one class on the items of business listed on the proxy card.

- Directors are elected by a plurality of votes cast, so the eight nominees receiving the most votes will be elected. Stockholders who do not wish to vote for one or more of the individual nominees may withhold authority in the space provided on the proxy card. Abstentions and broker non-votes will count neither for nor against election.

- Ratifying the appointment of the independent registered public accounting firm for the fiscal year ending June 30, 2007 requires a majority of the votes cast on that item. Abstentions and broker non-votes will count neither for nor against ratification.
VOTING RIGHTS, SHARES OUTSTANDING AND VOTES PER SHARE

Holders of common stock and of Series A preferred stock at the close of business on the record date of October 19, 2006 are entitled to vote at the meeting.

Common stock: 70,904,881 shares outstanding, one vote per share

Series A preferred stock: 9,997 shares outstanding, approximately 38.61 votes per share, for a total of 385,979 votes

Table of Contents

ITEM 1: ELECTION OF DIRECTORS

We recommend voting FOR the eight nominees listed on the proxy card. At the meeting, the eight nominees who receive the most votes will be elected as directors to serve until the next annual meeting, or until their successors are elected and qualified. Each of the nominees is currently a director. If any of the nominees should become unavailable to serve on the board, the proxy holders will vote your shares for a board-approved substitute, or the board may reduce the number of directors.

THE NOMINEES

<table>
<thead>
<tr>
<th>Name</th>
<th>Age</th>
<th>Position with Palatin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carl Spana, Ph.D.</td>
<td>44</td>
<td>President, chief executive officer and director</td>
</tr>
<tr>
<td>John K.A. Prendergast, Ph.D.</td>
<td>52</td>
<td>Director, chairman of the board of directors</td>
</tr>
<tr>
<td>Perry B. Molinoff, M.D.</td>
<td>66</td>
<td>Director</td>
</tr>
<tr>
<td>Robert K. deVeer, Jr. (1)(2)(3)</td>
<td>60</td>
<td>Director</td>
</tr>
<tr>
<td>Zola P. Horovitz, Ph.D. (1)(2)(3)</td>
<td>72</td>
<td>Director</td>
</tr>
<tr>
<td>Robert I. Taber, Ph.D. (1)(2)</td>
<td>70</td>
<td>Director</td>
</tr>
<tr>
<td>Errol De Souza (2)(3)</td>
<td>52</td>
<td>Director</td>
</tr>
<tr>
<td>J. Stanley Hull</td>
<td>54</td>
<td>Director</td>
</tr>
</tbody>
</table>

(1) Member of the audit committee.
(2) Member of the compensation committee.
CARL SPANA, Ph.D., co-founder of Palatin, has been our president and chief executive officer since June 14, 2000. He has been a director of Palatin since June 1996 and has been a director of our wholly-owned subsidiary, RhoMed Incorporated, since July 1995. From June 1996 through June 14, 2000, Dr. Spana served as an executive vice president and our chief technical officer. From June 1993 to June 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. Through his work at Paramount Capital Investments and The Castle Group, Dr. Spana co-founded and acquired several private biotechnology firms. From July 1991 to June 1993, Dr. Spana was a Research Associate at Bristol-Myers Squibb, a publicly traded pharmaceutical company, where he was involved in scientific research in the field of immunology. Dr. Spana is a director of AVAX Technologies, Inc., a publicly traded medical technology company. Dr. Spana received his Ph.D. in molecular biology from The Johns Hopkins University and his B.S. in biochemistry from Rutgers University.

JOHN K.A. PRENDERGAST, Ph.D., co-founder of Palatin, has been chairman of the board since June 14, 2000, and a director since August 1996. Dr. Prendergast has been president and sole stockholder of Summercloud Bay, Inc., a biotechnology consulting firm, since 1993. He is a co-founder and/or a member of the board of Ingenex, Inc., Avigen, Inc., AVAX Technologies, Inc. and Medicinova, Inc. From October 1991 through December 1997, Dr. Prendergast was a managing director of The Castle Group Ltd. Dr. Prendergast received his M.Sc. and Ph.D. from the University of New South Wales, Sydney, Australia and a C.S.S. in administration and management from Harvard University.

PERRY B. MOLINOFF, M.D. has been a director since November 2001. He served as our executive vice president for research and development from September 2001 until November 3, 2003, when he resigned to accept a position as Vice Provost for Research at the University of Pennsylvania. He is also a director of Cypress Bioscience, Inc. Dr. Molinoff's has more than 30 years of experience in both the industrial and educational sectors. From 1981 to 1994, he was a professor of pharmacology and chairman of the Department of Pharmacology at the University of Pennsylvania School of Medicine in Philadelphia. From January 1995 until March 2001, he was vice president of neuroscience and genitourinary drug discovery for the Bristol-Myers Squibb Pharmaceutical Research Institute, where he was responsible for directing and implementing the Institute's research efforts. Dr. Molinoff earned his medical degree from Harvard Medical School.

ROBERT K. deVEER, Jr. has been a director since November 1998. Since January 1997, Mr. deVeer has been the president of deVeer Capital LLC, a private investment company. From 1995 until his retirement in 1996, Mr. deVeer served as Managing Director, Head of Industrial Group at New York-based Lehman Brothers. From 1973 to 1995, he held increasingly responsible positions at New York-based CS First Boston, including Head of Project Finance, Head of Industrials and Head of Natural Resources. He was a managing director, member of the investment banking committee and a trustee of the First Boston Foundation. He received a B.A. in economics from Yale University and an M.B.A. in finance from Stanford Graduate School of Business.

ZOLA P. HOROVITZ, Ph.D. has been a director since February 2001. Before he retired from Bristol-Myers Squibb in 1994, Dr. Horovitz spent 34 years in various positions, including associate director of the Squibb Institute for Medical Research, vice president of development, vice president, scientific liaison, vice president of licensing, and

Table of Contents
vice president of business development and planning for the pharmaceutical division of Bristol-Myers Squibb. He held advisory positions at the University of Pittsburgh, Rutgers College of Pharmacy and Princeton University. He is also currently a director of the following publicly-held companies: Genaera Corporation, Biocryst Pharmaceuticals, Inc., Avigen, Inc., Dov Pharmaceutical, Inc., NitroMed, Inc., GenVec, Inc. and Immunicon Corporation. Dr. Horovitz earned his Ph.D. in pharmacology from the University of Pittsburgh.

ROBERT I. TABER, Ph.D. has been a director since May 2001. Dr. Taber began his career in the pharmaceutical industry in 1962, holding a succession of positions within Schering Corporation's biological research group before leaving in 1982 as director of biological research. He has also held a number of increasingly important positions with DuPont Pharmaceuticals and the DuPont Merck Pharmaceutical Company, including director of pharmaceutical research, director of pharmaceutical and biotechnology research, vice president of pharmaceutical research and vice president of extramural research and development. From 1994 to 1998, Dr. Taber held the position of senior vice president of research and development at Synaptic Pharmaceuticals Corporation before founding Message Pharmaceuticals, Inc. in 1998. Dr. Taber earned his Ph.D. in pharmacology from the University of Pittsburgh.

ERROL DE SOUZA, Ph.D. has been a director since April 2003. Dr. De Souza has nearly two decades of experience in the field of drug discovery and development. Dr. De Souza joined Archemix Corporation, a biopharmaceutical company focused on aptamer therapeutics, on April 1, 2003. From September 2002 to March 2003, he was president and chief executive officer and a director of Synaptic Pharmaceuticals. As a result of a merger effective March 2003, Synaptic Pharmaceuticals became a wholly owned subsidiary of H. Lundbeck A/S, an international pharmaceutical company. Prior to that, Dr. De Souza held senior management positions with Aventis, and its predecessor company Hoechst Marion Roussel Pharmaceuticals, and was co-founder of Neurocrine Biosciences, Inc. He is currently a director of IDEXX Laboratories, Inc. and Targacept, Inc. and a professor at the Center for Molecular Biology and Behavioral Neurosciences at Rutgers University. Dr. De Souza received his B.A. (Honors) in physiology and his Ph.D. in neuroendocrinology from the University of Toronto and he received his postdoctoral fellowship in neuroscience from The John Hopkins School of Medicine.

J. STANLEY HULL has been a director since September 2005. Mr. Hull has nearly three decades of experience in the field of sales and marketing. Mr. Hull joined GlaxoSmithKline, a research-based pharmaceutical company in October 1987 and is currently Senior Vice President for the US Pharmaceuticals — RTP Business Division. Prior to his current position, he served in the R&D organization of GlaxoSmithKline as Vice President and Worldwide Director of Therapeutic Development and Product Strategy—Neurology and Psychiatry. Prior to that, he was Vice President of Marketing — Infectious Diseases and Gastroenterology for Glaxo Wellcome Inc. Mr. Hull started his career in the pharmaceutical industry with SmithKline and French Laboratories in 1978. Mr. Hull received his B.S. in business administration from the University of North Carolina at Greensboro.

All current directors were elected at our last annual stockholders’ meeting on December 2, 2005.

THE BOARD AND ITS COMMITTEES

Committees and meetings. The board has an audit committee, a compensation committee and a nominating and corporate governance committee. During the fiscal year ended June 30, 2006, the board met four times, the audit committee met four times, the compensation committee met once and the nominating and corporate governance committee met twice. Each director has attended at least 75% of the total number of meetings of the
board and committees of the board on which he served. With the exception of Dr. Spana, the directors did not attend the 2005 annual meeting.

**Audit committee.** We have a separately designated standing audit committee as defined in Section 3(a)(58)(A) of the Exchange Act. The audit committee reviews the engagement of the independent registered public accounting firm and reviews the independence of the registered public accounting firm. The audit committee also reviews the audit and non-audit fees of the registered public accounting firm and the adequacy of our internal control procedures. The audit committee is currently composed of three non-employee directors, Messrs. deVeer, Horovitz and Taber. The board has determined that the members of the audit committee are independent, as defined in Section 121(A) of the American Stock Exchange listing requirements, and satisfy the requirements of the American Stock Exchange as to financial literacy and expertise. The board has determined that at least one member, Robert K. deVeer, is an audit committee financial expert as defined by the Securities and Exchange Commission (the "SEC"). The responsibilities of the audit committee are set forth in a written charter adopted by the board, a copy of which is available on our web site at www.palatin.com. The report of the audit committee appears under Item 2 below.

**Compensation committee.** The compensation committee reviews and recommends to the board remuneration arrangements, compensation plans and option grants for our officers, key employees, directors and others, and administers our 2005 stock plan and outstanding grants under other option plans. The compensation committee is composed of Messrs. deVeer, Horovitz, Taber and De Souza. The report of the compensation committee appears below, after the section on executive compensation.

**Nominating and corporate governance committee.** The nominating and corporate governance committee assists the board in determining qualified individuals to become directors; assists the board in determining the composition of committees; and reviews, assesses and makes recommendations to the board concerning policies and guidelines for corporate governance, including relationships of the board, the stockholders and management in determining Palatin's direction and performance. The nominating and corporate governance committee is composed of Messrs. deVeer, Horovitz and De Souza, each of whom meets the independence requirements and standards currently established by the American Stock Exchange.

The nominating and corporate governance committee will consider stockholder recommendations of nominees for election to the board of directors if they are accompanied by a comprehensive written resume of the recommended nominee's business experience and background and a signed consent from the recommended nominee stating that he or she is willing to be considered as a nominee and, if nominated and elected, will serve as a director. Stockholders may send their written recommendations with the required documentation to our executive offices at 4C Cedar Brook Drive, Cranbury, NJ 08512, Attention: Secretary, no later than the deadline for stockholder proposals specified under “Stockholder Proposals for Next Annual Meeting” on page 20.

---

**Table of Contents**

For all potential candidates, the nominating and corporate governance committee may consider all factors it deems relevant, such as a candidate's personal integrity and sound judgment, business and professional skills and experience, independence, knowledge of the industry in which we operate, possible conflicts of interest, diversity, the extent to which the candidate would fill a present need on the board and concern for the long-term interests of the stockholders. As set forth in the committee charter, persons recommended by stockholders will be considered on the same basis as candidates from other sources. The nominating and corporate governance committee may retain search firms to assist in identifying suitable director candidates. A copy of the committee's written charter is available on our website.
Shareholder communications to the board. Generally, stockholders who have questions or concerns should contact Stephen T. Wills, Secretary, Palatin Technologies, Inc., 4C Cedar Brook Drive, Cranbury, NJ 08512. However, any stockholders who wish to address questions regarding our business directly to the board of directors, or any individual director, should direct his or her questions to the non-employee Board members via e-mail at boardofdirectors@palatin.com.

Duration of office. Unless a director resigns, all directors hold office until the next annual meeting of stockholders or until their successors have been elected and qualified.

Code of conduct and ethics. We have adopted a code of conduct and ethics that applies to all of our directors and employees, including our chief executive officer and chief financial and accounting officer. You can view the code of conduct and ethics at our website, www.palatin.com. We will disclose any amendments to, or waivers from, provisions of the code of conduct and ethics that apply to our directors, principal executive and financial officers in a current report on Form 8-K, unless the rules of the American Stock Exchange permit website posting of any such amendments or waivers.

COMPENSATION OF DIRECTORS

Non-employee directors' initial option grants. When a non-employee director is first elected to the board, he receives an option to purchase 20,000 shares of common stock, at the market value on the date of grant. These options vest as to 25% of the option per year, starting on the date of grant. They expire 10 years from the date of grant.

Non-employee directors' annual option grants. Annually, on July 1, the first day of the fiscal year, each non-employee director receives an option to purchase 20,000 shares of common stock at the closing price on the preceding business day, which vests in twelve monthly installments beginning July 31. They expire 10 years from the date of grant. Messrs. De Souza, deVeer, Horovitz, Molinoff, Taber and Hull each received an option on July 1, 2006 to purchase 20,000 shares at $2.00 per share, the closing price on June 30, 2006.

Non-employee directors' cash compensation. Dr. Prendergast serves as chairman of the board and receives an annual retainer of $60,000, payable quarterly. Other non-employee directors receive an annual retainer of $8,000, payable on a quarterly basis, plus $2,000 per in-person board meeting, $300 per telephonic board meeting and $500 per committee meeting. A committee chairperson receives an additional $500 per committee meeting.

Non-employee directors' expenses. Non-employee directors are reimbursed for expenses incurred in performing their duties as directors, including attending all meetings of the board and any committees on which they serve.

Employee directors. Employee directors are not separately compensated for services as directors, but are reimbursed for expenses incurred in performing their duties as directors, including attending all meetings of the board and any committees on which they serve.

Table of Contents

ITEM 2: RATIFICATION OF APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We recommend voting FOR the ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2007. KPMG served as our independent registered public accounting firm for the fiscal year ended June 30, 2006. We expect that a representative of KPMG will attend the annual meeting. The representative will have an opportunity to make a statement, if he or she desires, and will be available to respond to appropriate questions from stockholders.

**Audit Fees.** For the fiscal year ended June 30, 2006, KPMG billed us a total of $299,000 for professional services rendered for the audit of our annual financial statements, review of financial statements in our Forms 10-Q, evaluation of the effectiveness of our internal control over financial reporting and services provided in connection with regulatory filings. For the fiscal year ended June 30, 2005, the total billed for the same services was $276,200.

**Audit-Related Fees.** For the fiscal years ended June 30, 2006 and 2005, KPMG did not perform or bill us for any audit-related services.

**Tax Fees.** For the fiscal year ended June 30, 2006, we anticipate that KPMG will bill us a total of $15,000 for professional services rendered for tax compliance, tax advice and tax planning. For the fiscal year ended June 30, 2005, KPMG billed us $12,600 for professional services rendered for tax compliance, tax advice and tax planning.

**All Other Fees.** KPMG did not perform or bill us for any services other than those described above for the fiscal years ended June 30, 2006 and 2005.

**Policy on Audit Committee Pre-Approval of Audit and Permissible Non-audit Services of Independent Auditors.** Consistent with SEC policies regarding auditor independence, the audit committee has responsibility for appointing, setting compensation for and overseeing the work of the independent registered public accounting firm. In recognition of this responsibility, the audit committee has established a policy to pre-approve all audit and permissible non-audit services provided by the independent registered public accounting firm.

Before engaging the independent registered public accounting firm for the next year's audit, management will submit to the audit committee for approval an estimate of fees for services expected to be rendered during that year in each of four categories:

- **Audit services,** including audit work performed, as well as work that generally only our independent registered public accounting firm can reasonably be expected to provide, including services provided in connection with regulatory filings, statutory audits and attest services and consultation regarding financial accounting and/or reporting standards;

- **Audit-related services,** including assurance and related services that are traditionally performed by the independent registered public accounting firm, including due diligence related to mergers and acquisitions, employee benefit plan audits and special procedures required to meet certain regulatory requirements;

- **Tax services,** including services performed by our independent registered public accounting firm's tax personnel except those services specifically related to the audit of the financial statements, including fees in the areas of tax compliance, tax planning and tax advice; and

- **All other services** not described in the preceding categories. We generally do not request other services from our independent registered public accounting firm.
The audit committee pre-approves fees for each category of service. The fees are budgeted and the audit committee requires the independent registered public accounting firm and management to report actual fees versus the budget periodically throughout the year by category of service. During the year, circumstances may arise when it may become necessary to engage the independent auditor for additional services not contemplated in the original pre-approval. In those instances, the audit committee requires specific pre-approval before engaging the independent registered public accounting firm.

The audit committee may delegate pre-approval authority to one or more of its members. The member to whom such authority is delegated must report, for informational purposes only, any pre-approval decisions to the audit committee at its next scheduled meeting.

In the event the stockholders do not ratify the appointment of KPMG as our independent registered public accounting firm, the audit committee will reconsider its appointment.

**REPORT OF THE AUDIT COMMITTEE**

We have reviewed and discussed the audited financial statements for the fiscal year ended June 30, 2006 with the Company's management and have discussed with KPMG LLP the matters required to be discussed by Statement on Auditing Standards No. 61, *Communication with Audit Committees*. In addition, we have received from KPMG LLP the written disclosures and the letter required by the Independence Standards Board Standard No.1, *Independence Discussions with Audit Committees*, and we have discussed with KPMG LLP their independence.

Based on these reviews and discussions, we recommended to the board of directors that the audited financial statements be included in the Company's annual report on Form 10-K for the fiscal year ended June 30, 2006.

**THE AUDIT COMMITTEE**

Robert K. deVeer, Jr., Chairman

Zola P. Horovitz, Ph.D.

Robert I. Taber, Ph.D.

**EXECUTIVE OFFICERS**

<table>
<thead>
<tr>
<th>Name</th>
<th>Age</th>
<th>Position with Palatin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carl Spana, Ph.D.</td>
<td>44</td>
<td>President, chief executive officer and director</td>
</tr>
<tr>
<td>Stephen T. Wills, CPA</td>
<td>49</td>
<td>Executive vice president of operations and chief financial officer, secretary and treasurer</td>
</tr>
</tbody>
</table>
Executive officers are appointed by the board and serve at the discretion of the board. Each officer holds his position until his successor is appointed and qualified. All of the current executive officers hold office under employment agreements.

Additional information about Dr. Spana is included under Item 1, Election of Directors.

STEPHEN T. WILLS, CPA, MST, has been vice president, secretary, treasurer and chief financial officer since 1997 and has been executive vice president of operations since 2005. From July 1997 to August 2000, Mr. Wills was also a vice president and the chief financial officer of Derma Sciences, Inc., a publicly held company which provides wound and skin care products, and currently serves as a director of Derma. From 1991 to August 2000, he was the president and chief operating officer of Golomb, Wills & Company, P.C., a public accounting firm. Mr. Wills, a certified public accountant, received his B.S. in accounting from West Chester University, and an M.S. in taxation from Temple University.

TREVOR HALLAM, Ph.D., has been executive vice president of research and development since May 2005. From 1996 to 2005, Dr. Hallam held senior management positions within AstraZeneca R&D, including vice president of biologics based out of the UK, vice president of respiratory and inflammation research based in Sweden and vice president of medical affairs within the US. From 1985 to 1995, Dr. Hallam served in senior management positions within Smith Kline and French Research, Glaxo Group Research and Roche Research. Dr. Hallam joined the pharmaceutical industry after a post-doctoral fellowship at the Physiological Laboratory, University of Cambridge, UK. He earned his Ph.D. in biochemistry from the University of London and his B.Sc. from the University of Leeds.

SHUBH D. SHARMA, Ph.D., has been vice president and chief scientific officer since March 2006 and, prior to that, chief technical officer since August 2001. He had been our executive director of research since November 2000 and director of chemistry since 1996. He is the inventor of our MIDAS drug design technology platform. Dr. Sharma was associate director of research and development and director of peptide research for RhoMed Incorporated (now our wholly-owned subsidiary) at the time we merged with RhoMed in 1996, and had worked as director of peptide research for RhoMed since 1994. Previously he had worked on drug design and peptide research at the University of Arizona in Tucson, and at the Swiss Federal Institute of Technology in Zurich, Switzerland. Dr. Sharma received his Ph.D. from the Central Drug Research Institute in Lucknow, India.

**EXECUTIVE COMPENSATION**

*Summary compensation table.* The following table summarizes the compensation paid to our chief executive officer and the other named executive officers for the last three fiscal years. With respect to the persons and periods covered in the following table, we made no restricted stock awards, have no outstanding stock appreciation rights (“SARs”) and have no long-term incentive plan (“LTIP”).
### Option Grants in Last Fiscal Year

*Option grants in last fiscal year:* The following table shows options granted to our named executive officers during the fiscal year ended June 30, 2006. All of the options listed were granted under our 2005 stock plan, and the underlying security is common stock. The exercise price for each option is equal to or higher than the market price of common stock on the date of grant.

<table>
<thead>
<tr>
<th>Name and Principal Position</th>
<th>Fiscal Year</th>
<th>Salary</th>
<th>Bonus</th>
<th>Option Shares</th>
<th>All Other Compensation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carl Spana, Ph.D., president and chief executive officer</td>
<td>2006</td>
<td>$350,000</td>
<td>$100,000</td>
<td>158,000</td>
<td>$3,297</td>
</tr>
<tr>
<td></td>
<td>2005</td>
<td>$340,000</td>
<td>$260,000(3)</td>
<td>-</td>
<td>$3,209</td>
</tr>
<tr>
<td></td>
<td>2004</td>
<td>$320,000</td>
<td>$50,000</td>
<td>100,000</td>
<td>$3,805</td>
</tr>
<tr>
<td>Stephen T. Wills, CPA, executive vice president of operations and chief financial officer</td>
<td>2006</td>
<td>$285,000</td>
<td>$75,000</td>
<td>123,000</td>
<td>$6,684</td>
</tr>
<tr>
<td></td>
<td>2005</td>
<td>$275,000</td>
<td>$240,000(3)</td>
<td>-</td>
<td>$6,609</td>
</tr>
<tr>
<td></td>
<td>2004</td>
<td>$265,000</td>
<td>$40,000</td>
<td>80,000</td>
<td>$19,107</td>
</tr>
<tr>
<td>Trevor Hallam, Ph.D., executive vice president of research and development(4)</td>
<td>2006</td>
<td>$275,000</td>
<td>$75,000</td>
<td>-</td>
<td>$7,453</td>
</tr>
<tr>
<td></td>
<td>2005</td>
<td>$39,663</td>
<td>$25,000</td>
<td>350,000</td>
<td>$20</td>
</tr>
<tr>
<td>Shubh D. Sharma, Ph.D., vice president and chief scientific officer</td>
<td>2006</td>
<td>$201,900</td>
<td>-</td>
<td>70,000</td>
<td>$6,623</td>
</tr>
<tr>
<td></td>
<td>2005</td>
<td>$196,000</td>
<td>$95,000(3)</td>
<td>-</td>
<td>$6,549</td>
</tr>
<tr>
<td></td>
<td>2004</td>
<td>$185,000</td>
<td>$23,333</td>
<td>50,000</td>
<td>$19,107</td>
</tr>
</tbody>
</table>

(1) The security underlying all options listed is common stock.
(2) Health and disability insurance premiums were included in amounts reported for 2004. Amounts reported for 2006 include $234 of term life insurance premiums for each person and $3,063, $6,450, $7,219 and $6,389 of 401(k) matching contributions for Dr. Spana, Mr. Wills, Dr. Hallam and Dr. Sharma, respectively.
(3) Consists of performance-based payments for the achievement of regulatory approval for one of our products and the completion of a collaborative development agreement for another of our products.
(4) Dr. Hallam’s employment commenced May 2005.
<table>
<thead>
<tr>
<th>Name</th>
<th>(#)</th>
<th>Year</th>
<th>($/Sh)</th>
<th>Date</th>
<th>5% ($)</th>
<th>10% ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carl Spana</td>
<td>83,000(1)</td>
<td>7.6%</td>
<td>$1.75</td>
<td>7/1/2015</td>
<td>$91,347</td>
<td>$231,491</td>
</tr>
<tr>
<td></td>
<td>75,000(2)</td>
<td>6.9%</td>
<td>$3.75</td>
<td>7/1/2015</td>
<td>-</td>
<td>59,179</td>
</tr>
<tr>
<td>Stephen T. Wills</td>
<td>73,000(1)</td>
<td>6.7%</td>
<td>$1.75</td>
<td>7/1/2015</td>
<td>80,341</td>
<td>203,601</td>
</tr>
<tr>
<td></td>
<td>50,000(2)</td>
<td>4.6%</td>
<td>$3.75</td>
<td>7/1/2015</td>
<td>-</td>
<td>39,452</td>
</tr>
<tr>
<td>Shubh D. Sharma</td>
<td>35,000(1)</td>
<td>3.2%</td>
<td>$1.75</td>
<td>7/1/2015</td>
<td>38,250</td>
<td>97,617</td>
</tr>
<tr>
<td></td>
<td>35,000(2)</td>
<td>3.2%</td>
<td>$3.75</td>
<td>7/1/2015</td>
<td>-</td>
<td>27,617</td>
</tr>
</tbody>
</table>

*“Potential realizable value” is shown in response to SEC rules which require the information, for illustration purposes only. The values shown are not representations or projections of future stock prices or the future value of our common stock.

(1) The options vest at the rate of 25% on the date of grant and 25% per year beginning July 1, 2006.

(2) The options vest at the rate of 25% per year beginning July 1, 2006.

**AGGREGATED OPTION EXERCISES AND FISCAL YEAR-END OPTION VALUES**

Aggregated option exercises and fiscal year-end option values. No executive officer exercised any options during the fiscal year ended June 30, 2006. Fiscal year-end values in the following table are based on the closing price for the common stock, as reported on the American Stock Exchange on June 30, 2006, of $2.00 per share.

<table>
<thead>
<tr>
<th>Name</th>
<th>Shares Acquired on Exercise</th>
<th>Value Realized</th>
<th>Number of Securities Underlying Unexercised Options at June 30, 2006</th>
<th>Value of Unexercised In-the-Money Options at June 30, 2006</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Exercisable</td>
<td>Unexercisable</td>
</tr>
<tr>
<td>Carl Spana</td>
<td>-</td>
<td>$-</td>
<td>901,712</td>
<td>137,250</td>
</tr>
<tr>
<td>Stephen T. Wills</td>
<td>-</td>
<td>$-</td>
<td>669,500</td>
<td>104,750</td>
</tr>
<tr>
<td>Trevor Hallam</td>
<td>-</td>
<td>$-</td>
<td>125,000</td>
<td>225,000</td>
</tr>
<tr>
<td>Shubh D. Sharma</td>
<td>-</td>
<td>$-</td>
<td>188,750</td>
<td>61,250</td>
</tr>
</tbody>
</table>
TEN-YEAR OPTION REPRICINGS

Ten-year option repricings: We did not adjust or amend the exercise price of any stock options during the fiscal year ended June 30, 2006. The following table shows all option repricings for all executive officers at any time during the last 10 years.

<table>
<thead>
<tr>
<th>Name</th>
<th>Date</th>
<th>Number of Securities Underlying Options Repriced or Amended</th>
<th>Market Price of Stock at Time of Repricing or Amendment</th>
<th>Exercise Price at Time of Repricing or Amendment</th>
<th>New Exercise Price</th>
<th>Length of Original Option Term Remaining at Date of Repricing or Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carl Spana</td>
<td>3/24/98</td>
<td>74,196</td>
<td>$6.25</td>
<td>$4.96</td>
<td>$1.00</td>
<td>8 years 3 months</td>
</tr>
<tr>
<td>Charles Putnam(1)</td>
<td>3/24/98</td>
<td>74,196</td>
<td>$6.25</td>
<td>$4.96</td>
<td>$1.00</td>
<td>8 years 3 months</td>
</tr>
<tr>
<td>Edward J. Quilty(2)</td>
<td>3/24/98</td>
<td>7,803</td>
<td>$6.25</td>
<td>$4.96</td>
<td>$0.20</td>
<td>9 years 2 months</td>
</tr>
</tbody>
</table>

(1) Former executive vice president and chief operating officer.
(2) Former president and chief executive officer.

EMPLOYMENT AGREEMENTS

Carl Spana, Ph.D. and Stephen T. Wills. Dr. Spana and Mr. Wills each entered into an employment agreement with us for a two-year period commencing October 1, 2005. Dr. Spana is serving as chief executive officer and president at a present salary of $370,000 per year. Mr. Wills is serving as executive vice president of operations and chief financial officer at a present salary of $305,000 per year. Each agreement also provides for:

- annual bonus compensation, in an amount to be decided by the compensation committee and approved by the board, based on achievement of yearly objectives; and
- participation in all benefit programs that we establish, to the extent the employee's position, tenure, salary, age, health and other qualifications make him eligible to participate.

Each agreement allows us or the employee to terminate the agreement upon written notice, and contains other provisions for termination by the Company for “cause,” or by the employee for “good reason” or due to a “change in control” (as these terms are defined in the employment agreements). Early termination may, in some circumstances, result in severance pay at the salary then in effect, for a period of 24 months (Spana) or 18 months (Wills), plus continuation of medical and dental benefits then in effect for 18 months. Termination following a change in control will result in a lump sum payment of two times (Spana) or one and one-half times (Wills) the salary then in effect, continuation of medical and dental benefits then in effect for 18 months and immediate vesting of all stock options. Each agreement includes non-competition, non-solicitation and confidentiality covenants.
Trevor Hallam, Ph.D. Dr. Hallam entered into an employment agreement with us for a two-year period commencing May 9, 2005. Dr. Hallam is serving as executive vice president of research and development at a present salary of $305,000 per year. His agreement also provides for:

- annual bonus compensation, in an amount to be decided by the compensation committee and approved by the board, based on achievement of yearly objectives; and
- participation in all benefit programs that we establish, to the extent the employee's position, tenure, salary, age, health and other qualifications make him eligible to participate.

The agreement allows us or the employee to terminate the agreement upon written notice, and contains other provisions for termination by the Company for “cause” (as defined in the agreement). Early termination may, in some circumstances, result in severance pay at the salary then in effect, for a period of 18 months. Termination following a change in control will result in a lump sum payment of one and one-half times the salary then in effect, continuation of medical and dental benefits then in effect for 18 months and immediate vesting of all stock options. The agreement includes non-competition and confidentiality covenants.

Shubh D. Sharma, Ph.D. Dr. Sharma entered into an employment agreement with us for a two-year period commencing October 1, 2005. Dr. Sharma is serving as a vice president and chief scientific officer at a present salary of $201,900 per year. His agreement also provides for:

- annual bonus compensation, in an amount to be decided by the compensation committee and approved by the board, based on achievement of yearly objectives; and
- participation in all benefit programs that we establish, to the extent the employee's position, tenure, salary, age, health and other qualifications make him eligible to participate.

The agreement allows us or the employee to terminate the agreement upon written notice, and contains other provisions for termination by the Company for “cause” (as defined in the agreement). Early termination may, in some circumstances, result in severance pay at the salary then in effect, for a period of nine months. The agreement includes non-competition and confidentiality covenants.

The board of directors established target bonuses for the fiscal year ending June 30, 2007 of up to 33% of base salary for Mr. Wills and Dr. Hallam and up to 40% of base salary for Dr. Spana, subject to an evaluation of their achievement of specified corporate objectives.

COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION IN COMPENSATION DECISIONS

During the fiscal years ended June 30, 2006 and 2005, Mr. deVeer, Dr. Horovitz, Dr. Taber and Dr. De Souza served on the compensation committee.

There are no compensation committee interlocks with other companies.
COMPENSATION COMMITTEE REPORT

The compensation committee of the board makes recommendations to the board about compensation of executive officers. The committee also administers the 2005 stock plan and our other stock option plans and may grant options or other stock-based awards to non-management employees and consultants, but it is the board's policy to have the full board review and approve all option grants or other stock-based awards that the committee recommends for executive officers and directors. The committee also reviews and makes recommendations to the board concerning proposed employment agreements with executive officers. The committee evaluates performance and determines compensation policies and levels for executive officers. The members of the compensation committee are not, and have never been, employees or executive officers of Palatin. Mr. deVeer has served on the committee since August 2000, Dr. Horovitz has served on the committee since February 2001, Dr. De Souza has served on the committee since April 2003 and Dr. Taber has served on the committee since October 2003.

Executive compensation policy. Competition for qualified senior management personnel in Palatin's industry is intense. In order to attract and retain qualified personnel, Palatin must offer compensation which is both comparable to similarly situated companies in current salary and benefits, and includes the potential for substantial rewards if Palatin is successful over the long term. Palatin's aim is to attract, retain and reward executive officers and other key employees who contribute to its long-term success and to motivate those individuals to enhance long-term stockholder value. To establish this relationship between executive compensation and creation of stockholder value, the board has adopted a total compensation package comprised of base salary, bonus and stock-based awards. It is Palatin's policy to enter into employment agreements with executive officers, preferably with an initial term of two years. Key elements of the compensation philosophy are:

- Palatin pays compensation at levels competitive with other biotechnology companies with which Palatin competes for talent.
- Palatin maintains annual incentive opportunities sufficient to provide motivation to achieve specific operating goals and to generate rewards that bring total compensation to competitive levels.

Determining executive compensation. The committee usually meets twice per year to review how well management compensation is serving Palatin's goals, to make recommendations to the board for any adjustments, and to recommend annual compensation for the coming year. Palatin's chief financial officer and human resources manager gather and report on information about compensation levels in comparable companies. We review the performance of each executive officer and the financial condition of the Company. We then consider the following major components of executive compensation:

Base salary. The employment agreement with each executive sets an initial base salary, which we believe was competitive in our industry, given the executive's experience and qualifications, at the time we entered into the agreement. The committee annually reviews each executive officer's base salary. Among the factors taken
into consideration during this annual review are (1) individual and corporate performance, (2) levels of responsibility, (3) prior experience, (4) breadth of knowledge of the industry and (5) competitive pay practices. If salaries at comparable companies appear to have increased, we recommend similar increases, but only if each executive’s historical performance warrants an increase and if the increase is prudent in view of Palatin’s financial condition.

**Annual bonus.** In addition to the competitive base salary, we intend to reward executives each year for the achievement of specific goals, which may be financial, operational or technological. We consider objectively measurable goals, such as obtaining new investment capital, negotiating valuable contracts or meeting regulatory requirements, and more subjective goals, such as quality of management performance and consistency of effort. Palatin’s objectives consist of operating, strategic and financial goals that the board considers to be critical to Palatin’s overall goal of building stockholder value. Our recommendations for cash bonuses also take into account Palatin’s liquidity and capital resources at the time. Until Palatin’s operations generate substantial income, we may recommend bonuses which consist partly or mainly of stock options. Stock options granted as part of bonus compensation will usually be immediately exercisable, or will vest over a shorter time than other incentive options.

**Long-term incentives.** At present, Palatin’s only long-term incentive program is its 2005 stock plan. Palatin does not have a defined benefit pension plan and contributions to executives’ accounts under Palatin’s 401(K) plan are limited by federal tax regulations. Through option grants and restricted stock grants, executives receive significant equity incentives to build long-term stockholder value. The exercise price of options granted under the plan is at least 100% of fair market value of the common stock on the date of grant. Employees receive value from these grants only if the common stock appreciates over the long-term. We determine the size and terms of option grants and restricted stock grants based on competitive practices at leading companies in the biotechnology industry and Palatin’s philosophy of significantly linking executive compensation with stockholder interests.

**Fiscal year 2006 compensation.** During the fiscal year ended June 30, 2006, under employment agreements with Dr. Spana, Mr. Wills, Dr. Hallam and Dr. Sharma, we provided for annual base salaries of $350,000 per year for Dr. Spana, $285,000 for Mr. Wills, $275,000 for Dr. Hallam and $201,900 for Dr. Sharma. The base salaries for these executive officers, as provided in their employment agreements, reflect comparable salary figures for the industry, necessary to engage and retain individuals with their skills. We granted cash bonuses to certain of these executive officers for fiscal 2006, reflecting the committee’s judgment concerning their attainment of a variety of operational objectives, including progress in our clinical development program for bremelanotide, the advance of our other development programs and the completion of financing arrangements. In the fiscal year ended June 30, 2006, we approved stock option grants for certain of these executive officers under the 2005 stock plan, a portion of which were granted with exercise prices substantially higher than the grant-date fair value of our stock. In determining the size and terms of these awards, we considered historical and comparable-company awards, including the omission of option grants for executives in fiscal 2005, and incentives for superior market performance of our common stock.

The base salary, bonus and grants of stock options for our chief executive officer, Carl Spana, Ph.D., were determined in accordance with the criteria described above under “Determining executive compensation.” Dr. Spana’s compensation reflects the board’s subjective assessment of (1) his performance, (2) his skills in relation to other chief executive officers in Palatin’s industry and (3) the board’s assessment of Palatin’s performance. Considering these factors, the committee set Dr. Spana’s base annual salary at $350,000 for the fiscal year ended June 30, 2006.
**Certain Tax Considerations**: Section 162(m) of the Internal Revenue Code limits the Company to a deduction for federal income tax purposes of not more than $1 million of compensation paid to certain executive officers in a taxable year. Compensation above $1 million may be deducted if it is “performance-based compensation” within the meaning of the Code.

The committee believes that at the present time it is unlikely that the compensation paid to any executive officer in a taxable year will exceed $1 million. Therefore, the board has not established a policy for determining which forms of incentive compensation awarded to executive officers will be designed to qualify as “performance-based compensation.”

SUBMITTED BY THE COMPENSATION COMMITTEE
Robert I. Taber, Ph.D. Chairman
Robert K. deVeer, Jr.
Zola P. Horovitz, Ph.D.
Errol De Souza, Ph.D.

**STOCK PERFORMANCE GRAPH**

The following graph compares the yearly change in the cumulative total shareholder return on our common stock with the cumulative total return on the Nasdaq Composite Index and the Nasdaq Biotechnology Index for the last five fiscal years, ending June 30, 2006. The graph assumes the investment of $100 in each stock or index on June 30, 2001, and the reinvestment of any dividends (we have never paid a dividend).

---

**STOCK OWNERSHIP INFORMATION**

**SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE**

The rules of the SEC require us to disclose late filings of reports of stock ownership and changes in stock ownership by our directors and officers. To the best of our knowledge, all of the filings for our directors and officers were made on a timely basis in the fiscal year ended June 30, 2006 except for reports related to July 1, 2005 option grants to Messrs. Spana, Wills, Prendergast, Molinoff, deVeer, Horovitz, Taber and De Souza, which were filed late.

**BENEFICIAL OWNERSHIP OF MANAGEMENT AND OTHERS**

The tables below show the beneficial stock ownership and voting power, as of October 19, 2006, of:

- each director, each of the named officers and all current directors and officers as a group; and
• all persons who, to our knowledge, beneficially own more than five percent of the common stock or Series A preferred stock.

“Beneficial ownership” here means direct or indirect voting or investment power over outstanding stock and stock which a person has the right to acquire now or within 60 days after October 19, 2006. Please see the footnotes for more detailed explanations of the holdings. Except as otherwise noted, to our knowledge, the persons named in the tables beneficially own and have sole voting and investment power over all shares listed.

The common stock has one vote per share and the Series A preferred stock has approximately 38.61 votes per share. Voting power is calculated on the basis of the aggregate of common stock and Series A preferred stock outstanding as of October 19, 2006. On October 19, 2006, 70,904,881 shares of common stock and 9,997 shares of Series A preferred stock were outstanding.

The address for all members of our management is c/o Palatin Technologies, Inc., 4C Cedar Brook Drive, Cranbury, NJ 08512. Addresses of other beneficial owners are in the footnotes to the table of beneficial owners.

### MANAGEMENT:

<table>
<thead>
<tr>
<th>Class</th>
<th>Name of Beneficial Owner</th>
<th>Shares</th>
<th>Percent of Class</th>
<th>Percent of Voting Power</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common</td>
<td>Carl Spana, Ph.D.</td>
<td>983,885 (1)</td>
<td>1.4%</td>
<td>*</td>
</tr>
<tr>
<td>Common</td>
<td>Stephen T. Wills</td>
<td>728,750 (2)</td>
<td>1.0%</td>
<td>*</td>
</tr>
<tr>
<td>Common</td>
<td>Trevor C. Hallam</td>
<td>127,500 (3)</td>
<td></td>
<td>*</td>
</tr>
<tr>
<td>Common</td>
<td>Shubh D. Sharma, Ph.D.</td>
<td>206,265 (4)</td>
<td></td>
<td>*</td>
</tr>
<tr>
<td>Common</td>
<td>John K.A. Prendergast, Ph.D.</td>
<td>466,840 (5)</td>
<td></td>
<td>*</td>
</tr>
<tr>
<td>Common</td>
<td>Perry B. Molinoff, M.D.</td>
<td>312,916 (6)</td>
<td></td>
<td>*</td>
</tr>
<tr>
<td>Common</td>
<td>Robert K. deVeer, Jr.</td>
<td>243,773 (7)</td>
<td></td>
<td>*</td>
</tr>
<tr>
<td>Common</td>
<td>Zola P. Horovitz, Ph.D.</td>
<td>138,333 (8)</td>
<td></td>
<td>*</td>
</tr>
<tr>
<td>Common</td>
<td>Robert I. Taber, Ph.D.</td>
<td>133,333 (9)</td>
<td></td>
<td>*</td>
</tr>
<tr>
<td>Common</td>
<td>Errol DeSouza, Ph.D.</td>
<td>87,083 (10)</td>
<td></td>
<td>*</td>
</tr>
<tr>
<td>Common</td>
<td>J. Stanley Hull</td>
<td>35,000 (11)</td>
<td></td>
<td>*</td>
</tr>
</tbody>
</table>

*Less than one percent.
Includes 941,212 shares which Dr. Spana has the right to acquire under options.

Includes 700,250 shares which Mr. Wills has the right to acquire under options.

Includes 125,000 shares which Dr. Hallam has the right to acquire under options.

Includes 206,250 shares which Dr. Sharma has the right to acquire under options.

Includes 449,167 shares which Dr. Prendergast has the right to acquire under options.

Includes 302,916 shares which Dr. Molinoff has the right to acquire under options.

Includes 242,773 shares which Mr. deVeer has the right to acquire under options.

Includes 133,333 shares which Dr. Horovitz has the right to acquire under options.

Includes 128,333 shares which Dr. Taber has the right to acquire under options.

Includes 87,083 shares which Dr. De Souza has the right to acquire under options.

Includes 35,000 shares which Mr. Hull has the right to acquire under options.

Includes 3,351,317 shares which directors and officers have the right to acquire under options.

5% OR GREATER BENEFICIAL OWNERS:

<table>
<thead>
<tr>
<th>Class</th>
<th>Name of Beneficial Owner</th>
<th>Shares</th>
<th>Percent of Class</th>
<th>Percent of Voting Power</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common</td>
<td>King Pharmaceuticals, Inc.(^{(1)})</td>
<td>6,630,580</td>
<td>9.2%</td>
<td>8.0%</td>
</tr>
<tr>
<td>Common</td>
<td>Lurie Investments(^{(3)})</td>
<td>4,285,984</td>
<td>6.0%</td>
<td>4.9%</td>
</tr>
<tr>
<td>Series A Preferred</td>
<td>J.F. Shea Co., Inc. (^{(5)})</td>
<td>5,000</td>
<td>50.0%</td>
<td>*</td>
</tr>
</tbody>
</table>

\(^{(1)}\) Address is 501 Fifth Street, Bristol, TN 37620.

\(^{(2)}\) Includes 955,119 shares which King has the right to acquire under warrants.

\(^{(3)}\) Includes the ownership of Lurie Investment Fund, LLC, ALFATECH, LLC, and WASK Investments, LLC. Mark Slezak is the investment manager for all three entities. Address is c/o Lurie Investments, 2 N. Riverside Plaza, Suite 1500, Chicago, IL 60606.

\(^{(4)}\) Includes 766,197 shares which Lurie Investment Fund, LLC, ALFATECH, LLC, and WASK Investments, LLC have the right to acquire under warrants.

\(^{(5)}\) Address is 655 Brea Canyon Road, Walnut, CA 91789.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

John K.A. Prendergast, Ph.D. In July 2003, we entered into an employment agreement with Dr. Prendergast, chairman of the board of directors, under which he received a salary of $50,000 in the fiscal year ended June 30, 2006. In addition, he participated in our health benefit programs, to the extent that his position, tenure, salary, age, health and other qualifications made him eligible to participate. Dr. Prendergast’s employment terminated September 30, 2006. Effective October 1, 2006, he will receive an annual retainer of $60,000 as a non-employee director for his services as chairman of the board.
Perry B. Molinoff, M.D. In November 2003, we entered into a consulting agreement with Dr. Molinoff under which we paid him $5,000 per month for consulting services. The consulting agreement expired in November 2004.

**OTHER ITEMS OF BUSINESS**

Other than the items of business discussed in this proxy statement, we are not aware of any matters that will come before the meeting. If other items of business properly come before the meeting, the proxy holders will vote shares in accordance with their judgment.

**STOCKHOLDER PROPOSALS FOR NEXT ANNUAL MEETING**

Stockholders may submit proposals on matters appropriate for stockholder action at annual meetings in accordance with regulations adopted by the SEC. To be considered for inclusion in the proxy statement and form of proxy relating to the next annual meeting of stockholders, such proposals must be received at our executive offices, 4C Cedar Brook Drive, Cranbury, NJ 08512, not later than July 11, 2007. Proposals should be directed to the attention of the Secretary.

For any proposal that is not submitted for inclusion in next year’s proxy statement (as described in the preceding paragraph) but is instead sought to be presented directly at next year’s annual meeting, SEC rules permit proxies to be voted at the discretion of management if (a) we receive notice of the proposal before the close of business on September 24, 2006 and we advise stockholders in next year’s proxy statement about the nature of the matter and how management intends to vote on such matter, or (b) we did not receive notice of the proposal prior to September 24, 2007.

**ANNUAL REPORT ON FORM 10-K**

Our annual report on Form 10-K for the fiscal year ended June 30, 2006, including the financial statements and schedules but excluding exhibits, is being sent with this proxy statement without charge to each person whose proxy is being solicited.

**INFORMATION INCORPORATED BY REFERENCE**

Notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act of 1933 or the Securities Exchange Act of 1934 that might incorporate this proxy statement in whole or in part, the audit committee report, the compensation committee report and the stock performance graph which follows the compensation committee report will not be deemed to be incorporated by reference into any such filing.

Your cooperation in giving this matter your immediate attention and returning your proxy card is greatly appreciated.

By order of the board of directors,

STEPHEN T. WILLS, Secretary

November 8, 2006

---

[proxy card front]
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

The undersigned appoints Carl Spana, Ph.D. and Stephen T. Wills (each with full power to act without the other) as proxy holders with full power of substitution, to vote all shares of common stock and Series A Convertible Preferred Stock of Palatin Technologies, Inc., a Delaware corporation, held of record by the undersigned as of October 19, 2006 at Palatin’s annual meeting of stockholders to be held Friday, December 15, 2006 and at any postponement or adjournment of the meeting.

(Continued and to be signed on reverse side)

ANNUAL MEETING OF STOCKHOLDERS OF

PALATIN TECHNOLOGIES, INC.

December 15, 2006

Please date, sign and mail your proxy card in the envelope provided as soon as possible.

Please detach along perforated line and mail in the envelope provided.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE ELECTION OF DIRECTORS AND “FOR” PROPOSAL 2. PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE x

1. Election of Directors:
   - NOMINEES
     - Carl Spana, Ph.D.
     - John K.A. Prendergast, Ph.D.
     - Perry B. Molinoff, M.D.
     - Robert K. deVeer, Jr.
     - Zola P. Horovitz, Ph.D.
     - Robert I. Taber, Ph.D.
     - Errol De Souza, Ph.D.
     - J. Stanley Hull
   - FOR ALL NOMINEES
   - WITHHOLD AUTHORITY FOR ALL NOMINEES
   - O FOR ALL EXCEPT
   (See instructions below)

2. To ratify the appointment of KPMG LLP as Palatin’s independent auditors for the fiscal year ending June 30, 2007.
   - FOR
   - AGAINST
   - ABSTAIN

3. In their discretion, the proxy holders are authorized to vote upon such other matters as may properly come before the meeting or any postponement or adjournment of the meeting.
   - FOR
   - AGAINST
   - ABSTAIN

The proxy holders will vote the shares of the undersigned stockholder as instructed above. If no choice is specified by the stockholder, the proxy holders will vote the shares FOR proposals no. 1, 2 and 3 and on any other matter coming before the meeting in the discretion of the proxy holders.
The undersigned revokes any proxy previously given to vote or act with respect to such shares and ratifies and confirms all actions which the proxy holders or their substitutes may lawfully do in accordance with the instructions on this proxy card.

Please complete, sign, date and return this proxy card in the enclosed envelope. No postage is required if mailed in the United States.

**INSTRUCTION:** To withhold authority to vote for any individual nominee(s), mark “FOR ALL EXCEPT” and fill in the circle next to each nominee you wish to withhold, as shown here: n

To change the address on your account, please check the box at right and indicate your new address in the address space above. Please note that changes to the registered name(s) on the account may not be submitted via this method.

<table>
<thead>
<tr>
<th>Signature of stockholder</th>
<th>Date:</th>
<th>Signature of stockholder</th>
<th>Date:</th>
</tr>
</thead>
</table>

**NOTE:** Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person.